Development of DEMQOL-U and DEMQOL-PROXY-U: Generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation

Health Technology Assessment

Volumn 17, Issue 5, 2013, Pages 1-160

  Mulhern, B ^a   Rowen, D ^a   Brazier, J ^a   Smith, S ^b   Romeo, R ^c   Tait, R ^c   Watchurst, C ^c   Chua, K C ^c   Loftus, V ^c   Young, T ^a   Lamping, D ^b   Knapp, M ^c,d   Howard, R ^c   Banerjee, S ^e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^e BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL EFFECTIVENESS; DEMENTIA; DEMQOL PROXY U QUESTIONNAIRE; DEMQOL U QUESTIONNAIRE; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH STATUS; HEALTH SURVEY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT CODING; PSYCHOMETRY; QUALITY OF LIFE;

COST-BENEFIT ANALYSIS; DEMENTIA; HEALTH CARE COSTS; HEALTH STATUS; HUMANS; PSYCHOMETRICS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84874196794     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17050     Document Type: Article

References (93)

1. Hofman A, Rocca WA, Brayne C, Breteler MM, Clarke M, Cooper B, et al. The prevalence of dementia in Europe. Int J Epidemiol 1991;20:736-48.
2. Launer LJ, Brayne C, Dartigues J-F, Hofman A. Epilogue. Neuroepidemiology 1992;11:119-21.
3. Knapp M, Prince, M, Albanese E, Banerjee S, Dhanasiri S, Fernandez J-L, et al. Dementia UK: the full report. London: Alzheimer's Society; 2007.
4. Lowin A, Knapp M, McCrone P. Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of research funding. Int J Geriatr Psychiatry 2001;16:1143-8.
5. Murray J, Schneider J, Banerjee S, Mann A. EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's dementia. II: a qualitative analysis of the experience of caregiving. Int J Geriatr Psych 1999;14:665-61.
6. Schneider J, Murray J, Banerjee S, Mann A. EUROCARE: a cross national study of co-resident spouse carers for people with Alzheimer's disease. I: factors associated with carer burden. Int J Geriatr Psych 1999;14:651-61.
7. Prince M, Jackson J. World Alzheimer's report 2009. London: Alzheimer's Disease International; 2009.
8. Wimo A, Prince M. World Alzheimer's Report 2010: the global economic impact of dementia. London: Alzheimer's Disease International; 2010.
9. Department of Health. National service framework for older people. London: Department of Health; 2001.
10. Department of Health. Everybody's business. London: Care Services Improvement Partnership; 2005.
11. Department of Health. Living well with dementia, a national dementia strategy. London: The Stationery Office; 2008.
12. National Audit Office. Improving services and support for people with dementia. Report by the Comptroller and Auditor General, HC 604, Session 2006-2007. London: The Stationery Office; 2007.
13. Whitehouse PJ. Harmonization of dementia drug guidelines: a report of the International Working Group for the Harmonization for Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 2000;14:S119-22.
14. Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, et al. Measurement of healthrelated quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess 2005;9(10).
15. Brod M, Stewart AL, Sands L, Walton P. Conceptualization and measurement of quality of life in dementia. Gerontologist 1999;39:25-35.
16. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults with cognitive impairments. Psychosomat Med 2002;64:510-19.
17. Smith SC, Lamping DL, Banerjee S, Harwood RH, Foley B, Smith P, et al. Development of a new measure of health-related quality of life for people with dementia: DEMQOL. Psychol Med 2007;37:737-46.
18. Banerjee S, Smith SC, Lamping DL, Harwood RH, Foley B, Smith P, et al. Quality of life in dementia: more than just cognition. J Neurol Neurosurg Psychiatry 2006;77:146-8.
19. Woods RT, Thorgrimsen L, Spector A, Royan L, Orrell M. Improved quality of life and cognitive stimulation in dementia. Aging Ment Health 2006;10:219-26.
20. Banerjee S, Samsi K, Petrie CD, Alvir J, Treglia M, Schwam EM, et al. What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia. Int J Geriatr Psychiatry 2009;24:15-25.
21. Banerjee S. The development of a new measure of health related quality of life for people with dementia - DEMQOL: use in research and clinical practice. J Alzheimers Dis Dement 2007;3:116-71.
22. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. NICE: London; 2006.
23. Brodaty H, Green A, Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc 2003;51:657-64.
24. Brooks R, EuroQol Group. EuroQol: the current state of play. Health Policy 1996;37:53-72.
25. Brazier JE, Roberts J, Deverill M. The estimation of a preference based measure of health from the SF-36. J Health Econ 2002;21:271-92.
26. Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82.
27. Tosh J, Brazier J, Evans P, Longworth L. A review of generic preference-based measures of healthrelated quality of life in visual disorders. Value Health 2012;15:118-27.
28. Longworth L, Mulhern B, Yang Y, Tosh J, Keetharuth A, Rowen D, et al. A systematic review of the performance of EQ-5D in four disease areas. EuroQol Group Scientific Meeting, Oxford, 2011.
29. Papaioannou D, Brazier J, Parry G. How valid and responsive are generic health status measures, such as the EQ-5D and SF-36, in schizophrenia? A systematic review. Value Health 2011;14:907-20.
30. Kavirajan H, Hays RD, Vassar S, Vickrey BG. Responsiveness and construct validity of the health utilities index in patients with dementia. Med Care 2009;47:651-61.
31. Coucill W, Bryan S, Bentham P, Buckley A, Laight A. ED-5D in patients with dementia. Med Care 2001;39:760-71.
32. Hounsome N, Orrell M, Edwards RT. EQ-5D as a quality of life measure in people with dementia and their carers: evidence and key issues. Value Health 2011;14:390-9.
33. Karlawish JH, Zbrozek A, Kinosian B, Gregory A, Ferguson A, Glick HA. Preference-based quality of life in patients with Alzheimer's disease. Alzheimers Dement 2008;4:193-202.
34. D2000 study group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000). Lancet 2004;363:2105-15.
35. Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006;10(1).
36. Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Ger Psych 2006;21:17-28.
37. Brazier JE, Rowen D, Mavranezouli I, Tsuchiya T, Yang Y, Barkham M, et al. Developing and testing methods for deriving preference-based measure of health from condition-specific measures (and other patient based measures of outcome). Health Technol Assess 2012;16(32).
38. Brazier J, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004;42:851-9.
39. Brazier JE, Ratcliffe J, Tsuchiya A, Salomon J. Measuring and valuing health for economic evaluation. Oxford: Oxford University Press; 2007.
40. Yang Y, Brazier J, Tsuchiya A, Young TA. Estimating a preference-based index for a 5-dimensional health state classification for asthma derived from the Asthma Quality of Life Questionnaire. Med Decis Making 2011;31:281-91.
41. Young T, Yang Y, Brazier J, Tsuchiya A. The use of Rasch analysis in reducing a large conditionspecific instrument for preference valuation: the case of moving from AQLQ to AQL-5D. Med Decis Making 2011;31:195-210.
42. Yang Y, Brazier J, Tsuchiya A, Coyne K. Estimating a preference-based single index from the Overactive Bladder Questionnaire. Value Health 2006;12:159-66.
43. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2004.
44. Gudex C. Time trade-off user manual: props and self-completion methods. York: University of York, Centre for Health Economics; 1994.
45. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
46. Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011;378:403-11.
47. Smith SC, Murray J, Banerjee S, Foley B, Cook JC, Lamping DL, et al. What constitutes health-related quality of life in dementia? Development of a conceptual framework for people with dementia and their carers. Int J Geriatr Psychiatry 2005;20:889-95.
48. Banerjee S, Willis R, Matthews D, Contell F, Chan J, Murray J. Improving the quality of care for mild to moderate dementia: an evaluation of the Croydon Memory Service Model. Int J Geriatr Psychiatry 2007;22:782-8.
49. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry 1988;23:271-84.
50. Folstein MF, Folstein SE, McHugh PR. Mini mental state. J Psychiatric Res 1975;12:189-98.
51. Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 1996;25:113-30.
52. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment psychopathology in dementia. Neurology 1994;44:2308-14.
53. EuroQol Group. EuroQol a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
54. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008. URL: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (accessed 2 September 2011).
55. Alexopoulos GS. The Cornell Scale for Depression in Dementia: administration and scoring guidelines 2002. URL: www.scalesandmeasures.net/files/files/The%20Cornell%20Scale%20for%20Depression%20in%20Dementia.pdf (accessed 31 August 2011).
56. Howard R, Phillips P, Johnson T, O'Brien J, Sheehan B, Lindesay J, et al. Determining the minimum clinically important differences for outcomes in the DOMINO trial. Int J Geriatr Psychiatry 2011;26:812-17.
57. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health states and quality of life instruments: attributes and review criteria. Qual Life Res 2002;11:193-205.
58. Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. Oxford: Oxford Medical Publications; 1995.
59. WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): development and general psychometric properties. Soc Sci Med 1998;46:1569-85.
60. Lamping DL, Hobart JC, Schroter S, Smith SC. Developing short-form outcome measures: methodological approaches to item reduction. In D Lamping (Chair), State of the art on item reduction: identifying the good, bad and ugly items: analysis and evaluation (Symposium). International Society for Quality of Life Research Annual Conference, Orlando, FL, 30 October-2 November 2002.
61. Lamping DL, Schroter S, Kurz X, Kahn SR, Abenhaim L. Evaluating outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. J Vasc Surg 2003;37:410-19.
62. Ferguson E, Cox T. Exploratory factor analysis: a user's guide. Int J Select Assess 1993;1:84-94.
63. Costello AB, Osborne JW. Best practices in exploratory factor analysis: four recommendations for getting the most from your analysis. PARE 2005;10:1-9.
64. Young T, Yang YL, Brazier JE, Tsuchiya A, Coyne K. The first stage of developing preferencebased measures: constructing a health-state classification using Rasch analysis. Qual Life Res 2009;18:253-65.
65. Prado-Jean A, Couratier P, Druet-Cabanac M, Nubukpo P, Bernard-Bourzeix L, Thomas P, et al. Specific psychological and behavioural symptoms of depression in patients with dementia. Int J Geriatr Psychiatry 2010;25:1065-72.
66. Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2008;23:170-7.
67. Young T, Rowen D, Norquist J, Brazier JE. Developing preference-based health measures: using Rasch analysis to generate health state values. Qual Life Res 2010;19:907-17.
68. Novella JL, Jochum C, Jolly D, Morrone I, Ankri J, Bureau F, et al. Agreement between patients' and proxies' reports of quality of life in Alzheimer's disease. Qual Life Res 2001;10:443-52.
69. Boyer F, Novella JL, Morrone I, Jolly D, Blanchard F. Agreement between dementia patient report and proxy reports using the Nottingham Health Profile. Int J Geriatr Psychiatry 2004;19:1026-34.
70. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996.
71. Rowen D, Brazier J, Tsuchiya A, Young T, Ibbotson R. It's all in the name, or is it? The impact of labelling on health state values. Med Decis Making 2012;32:31-40.
72. Rowen D, Brazier J, Young T, Gaugris S, Craig BM, King MT, et al. Deriving a preference-based measure for cancer using the EORTC QLQ-C30. Value Health 2011;14:721-31.
73. Mavranezouli I, Brazier J, Young A, Barkham M. Using Rasch analysis to form plausible health states amenable to valuation: the development of the CORE-6D from a measure of common mental health problems (CORE-OM). Qual Life Res 2011;20:321-33.
74. Federov VV. Theory of optimal experiments. New York, NY: Academic Press; 1972.
75. Salomon JA. Reconsidering the use of rankings in the valuation of health states: a model for estimating cardinal values from ordinal data. Popul Health Metr 2003;1:12.
76. McCabe C, Brazier J, Gilks P, Tsuchiya A, Roberts J, O'Hagan A, et al. Using rank data to estimate health state utility models. J Health Econ 2006;25:418-31.
77. Brazier J, Rowen D, Yang Y, Tsuchiya A. Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale. Eur J Health Econ 2012;13:575-87.
78. Brazier J, Rowen D, Tsuchiya A, Yang Y, Young TA. The impact of adding an extra dimension to a preference-based measure. Soc Sci Med 2011;73:245-53.
79. Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, et al. Should patients have a greater role in valuing health states? Appl Health Econ Health Policy 2005;4:201-8.
80. Dolders MGT, Zeegers MPA, Groot W, Ament A. A meta-analysis demonstrates no significant differences between patient and population preferences. J Clin Epidemiol 2006;59:653-64.
81. Boyd NF, Sutherland HJ, Heasman ZJ, Cummings BJ. Whose values for decision making? Med Decis Making 1990;10:58-67.
82. Brazier J. Measuring and valuing mental health for use in economic evaluation. J Health Serv Res Policy 2008;13:70-5.
83. Krabbe PFM, Tromp N, Ruers TJM, van Riel PLCM. Are patients' judgments of health status really different from the general population? Health Qual Life Outcomes 2011;9:31.
84. Insinga RP, Fryback DG. Understanding differences between self-ratings and population ratings for health in the EuroQOL. Qual Life Res 2003;12:611-19.
85. Dolan P, Roberts J. To what extent can we explain time trade-off values from other information about respondents? Soc Sci Med 2002;54:919-29.
86. Goldstein H. Multilevel statistical methods. New York, NY: Halstead Press; 1995.
87. Dolan P, Gudex C, Kind P, Williams A. Valuing health states: a comparison of methods. J Health Econ 1996;15:209-31.
88. Burns A, Lawlor B, Criag S. Rating scaes in old age psychiatry. Br J Psychiatry 2002;180:161-7.
89. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
90. Bharmal M, Thomas J. Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health 2006;9:262-71.
91. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420-8.
92. Mander A. BATPLOT: Stata module to produce Bland-Altman plots accounting for trend. Statistical Software Components, Boston College Department of Economics, 2005. URL: http://ideas.repec.org/c/boc/bocode/s448703.html (accessed 30 March 2011).
93. Cohen J. Statistical power analysis for the behavioral sciences. New York, NY: Academic Press; 1969.